Association of total bilirubin and indirect bilirubin content with metabolic syndrome among Kazakhs in Xinjiang

Background Some studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of transaminase is a risk factor for MS. However, the existing results are inconsistent and few cohort studies have been published. Methods Using an ambispecti...

Full description

Saved in:
Bibliographic Details
Published inBMC endocrine disorders Vol. 20; no. 1; pp. 1 - 7
Main Authors Hao, Hao, Guo, Heng, Ma, Ru-lin, Yan, Yi-zhong, Hu, Yun-hua, Ma, Jiao-long, Zhang, Xiang-hui, Wang, Xin-ping, Wang, Kui, Mu, La-ti, Song, Yan-peng, Zhang, Jing-yu, He, Jia, Guo, Shu-xia
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 22.07.2020
BioMed Central
BMC
Subjects
Age
Analysis
Bilirubin
Blood pressure
Cholesterol
Diabetes
Gender
Hypertension
Insulin resistance
Liver
Metabolic syndrome
Metabolites
Minority & ethnic groups
Population
Risk factors
Studies
Transaminase
Type 2 diabetes
Variables
Women
China
Online AccessGet full text
ISSN1472-6823
1472-6823
DOI10.1186/s12902-020-00563-y

Cover

Abstract Background Some studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of transaminase is a risk factor for MS. However, the existing results are inconsistent and few cohort studies have been published. Methods Using an ambispective cohort study, 565 Kazakhs from Xinjiang, China were selected as the study subjects. The baseline serum bilirubin and transaminase levels of the subjects were divided into quartiles and the relationship between these values and the incidence of MS was analyzed. The definition of MS was based on the Joint Interim Statement (JIS) diagnostic criteria. Results The average follow-up time for the subjects was 5.72 years. The cumulative incidence of MS was 36.11% (204 of the 565 subjects), and the incidence density was 63.10/1000 person-years. Multivariate Cox regression analysis showed that the levels of total bilirubin (TBIL) and indirect bilirubin (IBIL) were negatively correlated with the occurrence of MS, Compared to the lowest quartile level (Q1), the hazard ratios of MS the TBIL levels at the Q2-Q4 quartiles were: 0.47 (0.31-0.71), 0.53 (0.35-0.79), and 0.48 (0.32-0.72), respectively, while IBIL levels at the Q2-Q4 quartiles showed an MS hazard ratio of 0.48 (0.32-0.72), 0.54(0.36-0.81), and 0.52 (0.35-0.77), respectively, all at a 95% confidence level. However, no relationship was found between transaminase levels and the incidence of MS. Conclusion Serum TBIL and IBIL levels were negatively correlated with the incidence of MS in a Kazakh population in China. Keywords: Bilirubin, Transaminase, Metabolic syndrome
AbstractList Background Some studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of transaminase is a risk factor for MS. However, the existing results are inconsistent and few cohort studies have been published. Methods Using an ambispective cohort study, 565 Kazakhs from Xinjiang, China were selected as the study subjects. The baseline serum bilirubin and transaminase levels of the subjects were divided into quartiles and the relationship between these values and the incidence of MS was analyzed. The definition of MS was based on the Joint Interim Statement (JIS) diagnostic criteria. Results The average follow-up time for the subjects was 5.72 years. The cumulative incidence of MS was 36.11% (204 of the 565 subjects), and the incidence density was 63.10/1000 person-years. Multivariate Cox regression analysis showed that the levels of total bilirubin (TBIL) and indirect bilirubin (IBIL) were negatively correlated with the occurrence of MS, Compared to the lowest quartile level (Q1), the hazard ratios of MS the TBIL levels at the Q2-Q4 quartiles were: 0.47 (0.31-0.71), 0.53 (0.35-0.79), and 0.48 (0.32-0.72), respectively, while IBIL levels at the Q2-Q4 quartiles showed an MS hazard ratio of 0.48 (0.32-0.72), 0.54(0.36-0.81), and 0.52 (0.35-0.77), respectively, all at a 95% confidence level. However, no relationship was found between transaminase levels and the incidence of MS. Conclusion Serum TBIL and IBIL levels were negatively correlated with the incidence of MS in a Kazakh population in China. Keywords: Bilirubin, Transaminase, Metabolic syndrome
Background Some studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of transaminase is a risk factor for MS. However, the existing results are inconsistent and few cohort studies have been published. Methods Using an ambispective cohort study, 565 Kazakhs from Xinjiang, China were selected as the study subjects. The baseline serum bilirubin and transaminase levels of the subjects were divided into quartiles and the relationship between these values and the incidence of MS was analyzed. The definition of MS was based on the Joint Interim Statement (JIS) diagnostic criteria. Results The average follow-up time for the subjects was 5.72 years. The cumulative incidence of MS was 36.11% (204 of the 565 subjects), and the incidence density was 63.10/1000 person-years. Multivariate Cox regression analysis showed that the levels of total bilirubin (TBIL) and indirect bilirubin (IBIL) were negatively correlated with the occurrence of MS, Compared to the lowest quartile level (Q1), the hazard ratios of MS the TBIL levels at the Q2-Q4 quartiles were: 0.47 (0.31–0.71), 0.53 (0.35–0.79), and 0.48 (0.32–0.72), respectively, while IBIL levels at the Q2-Q4 quartiles showed an MS hazard ratio of 0.48 (0.32–0.72), 0.54(0.36–0.81), and 0.52 (0.35–0.77), respectively, all at a 95% confidence level. However, no relationship was found between transaminase levels and the incidence of MS. Conclusion Serum TBIL and IBIL levels were negatively correlated with the incidence of MS in a Kazakh population in China.
Some studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of transaminase is a risk factor for MS. However, the existing results are inconsistent and few cohort studies have been published.BACKGROUNDSome studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of transaminase is a risk factor for MS. However, the existing results are inconsistent and few cohort studies have been published.Using an ambispective cohort study, 565 Kazakhs from Xinjiang, China were selected as the study subjects. The baseline serum bilirubin and transaminase levels of the subjects were divided into quartiles and the relationship between these values and the incidence of MS was analyzed. The definition of MS was based on the Joint Interim Statement (JIS) diagnostic criteria.METHODSUsing an ambispective cohort study, 565 Kazakhs from Xinjiang, China were selected as the study subjects. The baseline serum bilirubin and transaminase levels of the subjects were divided into quartiles and the relationship between these values and the incidence of MS was analyzed. The definition of MS was based on the Joint Interim Statement (JIS) diagnostic criteria.The average follow-up time for the subjects was 5.72 years. The cumulative incidence of MS was 36.11% (204 of the 565 subjects), and the incidence density was 63.10/1000 person-years. Multivariate Cox regression analysis showed that the levels of total bilirubin (TBIL) and indirect bilirubin (IBIL) were negatively correlated with the occurrence of MS, Compared to the lowest quartile level (Q1), the hazard ratios of MS the TBIL levels at the Q2-Q4 quartiles were: 0.47 (0.31-0.71), 0.53 (0.35-0.79), and 0.48 (0.32-0.72), respectively, while IBIL levels at the Q2-Q4 quartiles showed an MS hazard ratio of 0.48 (0.32-0.72), 0.54(0.36-0.81), and 0.52 (0.35-0.77), respectively, all at a 95% confidence level. However, no relationship was found between transaminase levels and the incidence of MS.RESULTSThe average follow-up time for the subjects was 5.72 years. The cumulative incidence of MS was 36.11% (204 of the 565 subjects), and the incidence density was 63.10/1000 person-years. Multivariate Cox regression analysis showed that the levels of total bilirubin (TBIL) and indirect bilirubin (IBIL) were negatively correlated with the occurrence of MS, Compared to the lowest quartile level (Q1), the hazard ratios of MS the TBIL levels at the Q2-Q4 quartiles were: 0.47 (0.31-0.71), 0.53 (0.35-0.79), and 0.48 (0.32-0.72), respectively, while IBIL levels at the Q2-Q4 quartiles showed an MS hazard ratio of 0.48 (0.32-0.72), 0.54(0.36-0.81), and 0.52 (0.35-0.77), respectively, all at a 95% confidence level. However, no relationship was found between transaminase levels and the incidence of MS.Serum TBIL and IBIL levels were negatively correlated with the incidence of MS in a Kazakh population in China.CONCLUSIONSerum TBIL and IBIL levels were negatively correlated with the incidence of MS in a Kazakh population in China.
Abstract Background Some studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of transaminase is a risk factor for MS. However, the existing results are inconsistent and few cohort studies have been published. Methods Using an ambispective cohort study, 565 Kazakhs from Xinjiang, China were selected as the study subjects. The baseline serum bilirubin and transaminase levels of the subjects were divided into quartiles and the relationship between these values and the incidence of MS was analyzed. The definition of MS was based on the Joint Interim Statement (JIS) diagnostic criteria. Results The average follow-up time for the subjects was 5.72 years. The cumulative incidence of MS was 36.11% (204 of the 565 subjects), and the incidence density was 63.10/1000 person-years. Multivariate Cox regression analysis showed that the levels of total bilirubin (TBIL) and indirect bilirubin (IBIL) were negatively correlated with the occurrence of MS, Compared to the lowest quartile level (Q1), the hazard ratios of MS the TBIL levels at the Q2-Q4 quartiles were: 0.47 (0.31–0.71), 0.53 (0.35–0.79), and 0.48 (0.32–0.72), respectively, while IBIL levels at the Q2-Q4 quartiles showed an MS hazard ratio of 0.48 (0.32–0.72), 0.54(0.36–0.81), and 0.52 (0.35–0.77), respectively, all at a 95% confidence level. However, no relationship was found between transaminase levels and the incidence of MS. Conclusion Serum TBIL and IBIL levels were negatively correlated with the incidence of MS in a Kazakh population in China.
Some studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of transaminase is a risk factor for MS. However, the existing results are inconsistent and few cohort studies have been published. Using an ambispective cohort study, 565 Kazakhs from Xinjiang, China were selected as the study subjects. The baseline serum bilirubin and transaminase levels of the subjects were divided into quartiles and the relationship between these values and the incidence of MS was analyzed. The definition of MS was based on the Joint Interim Statement (JIS) diagnostic criteria. The average follow-up time for the subjects was 5.72 years. The cumulative incidence of MS was 36.11% (204 of the 565 subjects), and the incidence density was 63.10/1000 person-years. Multivariate Cox regression analysis showed that the levels of total bilirubin (TBIL) and indirect bilirubin (IBIL) were negatively correlated with the occurrence of MS, Compared to the lowest quartile level (Q1), the hazard ratios of MS the TBIL levels at the Q2-Q4 quartiles were: 0.47 (0.31-0.71), 0.53 (0.35-0.79), and 0.48 (0.32-0.72), respectively, while IBIL levels at the Q2-Q4 quartiles showed an MS hazard ratio of 0.48 (0.32-0.72), 0.54(0.36-0.81), and 0.52 (0.35-0.77), respectively, all at a 95% confidence level. However, no relationship was found between transaminase levels and the incidence of MS. Serum TBIL and IBIL levels were negatively correlated with the incidence of MS in a Kazakh population in China.
ArticleNumber 110
Audience Academic
Author Guo, Shu-xia
He, Jia
Zhang, Jing-yu
Wang, Kui
Yan, Yi-zhong
Zhang, Xiang-hui
Mu, La-ti
Ma, Jiao-long
Guo, Heng
Hu, Yun-hua
Song, Yan-peng
Hao, Hao
Ma, Ru-lin
Wang, Xin-ping
Author_xml – sequence: 1
  givenname: Hao
  surname: Hao
  fullname: Hao, Hao
– sequence: 2
  givenname: Heng
  surname: Guo
  fullname: Guo, Heng
– sequence: 3
  givenname: Ru-lin
  surname: Ma
  fullname: Ma, Ru-lin
– sequence: 4
  givenname: Yi-zhong
  surname: Yan
  fullname: Yan, Yi-zhong
– sequence: 5
  givenname: Yun-hua
  surname: Hu
  fullname: Hu, Yun-hua
– sequence: 6
  givenname: Jiao-long
  surname: Ma
  fullname: Ma, Jiao-long
– sequence: 7
  givenname: Xiang-hui
  surname: Zhang
  fullname: Zhang, Xiang-hui
– sequence: 8
  givenname: Xin-ping
  surname: Wang
  fullname: Wang, Xin-ping
– sequence: 9
  givenname: Kui
  surname: Wang
  fullname: Wang, Kui
– sequence: 10
  givenname: La-ti
  surname: Mu
  fullname: Mu, La-ti
– sequence: 11
  givenname: Yan-peng
  surname: Song
  fullname: Song, Yan-peng
– sequence: 12
  givenname: Jing-yu
  surname: Zhang
  fullname: Zhang, Jing-yu
– sequence: 13
  givenname: Jia
  surname: He
  fullname: He, Jia
– sequence: 14
  givenname: Shu-xia
  surname: Guo
  fullname: Guo, Shu-xia
BookMark eNp9kl9vFCEUxSemxv7RL-ATiS--TIULDMyLyabR2tjEF018Iwwwu6wzUIGtWT996W6N3cYYHiCXc37kXs5pcxRicE3zmuBzQmT3LhPoMbQYcIsx72i7fdacECag7STQo0fn4-Y05zXGREjAL5pjCl0vpexPmrjIORqvi48BxRGVWPSEBj_5tBl8QDpY5IP1yZnyqGxiKC4U9MuXFZpd0UOcvEF5G2yKs0N6jmGJPuvf-scqVwD67sPa67B82Twf9ZTdq4f9rPn28cPXi0_t9ZfLq4vFdWs4w6Vlgrth5ANxlggihB0t5a4fTc87bYmVYCj0otcdZRzYSETfW4KBAKUwCkPPmqs910a9VjfJzzptVdRe7QoxLZVOxZvJKcoYlhaMAzcykHygPQUpB-r4oBmGynq_Z91shtlZUxtPejqAHt4Ev1LLeKsEFV3fsQp4-wBI8efG5aJmn42bJh1c3GQFDDpOBSO4St88ka7jJoU6qqqiHChwyv-qlro24MMY67vmHqoWHSU1FUzIqjr_h6ou62Zff9CNvtYPDHJvMCnmnNyojC-7aFSjnxTB6j54ah88VYOndsFT22qFJ9Y_4_mP6Q7RCdt9
CitedBy_id crossref_primary_10_1161_CIR_0000000000001052
crossref_primary_10_1186_s12933_022_01484_x
crossref_primary_10_3390_jcm10132812
crossref_primary_10_3389_fendo_2022_869579
crossref_primary_10_1161_CIR_0000000000001209
crossref_primary_10_3390_diagnostics12010212
crossref_primary_10_1007_s12603_023_1965_2
crossref_primary_10_3390_metabo14070393
crossref_primary_10_1097_MD_0000000000039625
crossref_primary_10_1161_CIR_0000000000001303
crossref_primary_10_1161_CIR_0000000000001123
Cites_doi 10.1373/clinchem.2010.151043
10.1016/j.clindermatol.2017.09.004
10.3390/ijerph13040428
10.1016/j.dsx.2019.02.009
10.1016/j.bbrc.2009.06.029
10.1016/j.plipres.2012.11.001
10.1016/j.freeradbiomed.2015.05.031
10.1152/ajprenal.00039.2014
10.1038/srep44844
10.1186/s13098-019-0408-z
10.1038/srep36091
10.4103/1319-3767.157564
10.1161/CIRCULATIONAHA.112.105775
10.3346/jkms.2013.28.12.1768
10.1210/en.2013-1667
10.1016/j.trre.2018.06.003
10.1016/S0021-9258(19)89449-8
10.1016/0024-3205(94)90140-6
10.1155/2019/8267234
10.3389/fphar.2012.00055
10.1002/jcla.21967
10.1016/j.cca.2018.10.033
10.1007/s00592-012-0447-5
10.1016/j.molmed.2016.07.004
10.1042/CS20140566
10.1016/j.amjmed.2015.05.016
10.5152/tjg.2018.17333
10.1016/j.mehy.2006.12.069
10.1093/toxsci/kfx233
10.1161/CIRCULATIONAHA.109.192644
10.3892/mmr.2017.6825
10.1016/j.atherosclerosis.2006.04.006
ContentType Journal Article
Copyright COPYRIGHT 2020 BioMed Central Ltd.
2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2020
Copyright_xml – notice: COPYRIGHT 2020 BioMed Central Ltd.
– notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2020
DBID AAYXX
CITATION
3V.
7QP
7TK
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s12902-020-00563-y
DatabaseName CrossRef
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1472-6823
EndPage 7
ExternalDocumentID oai_doaj_org_article_34408d2ce2ef4285b393288b3e5ba402
PMC7376964
A631902478
10_1186_s12902_020_00563_y
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: ;
  grantid: 81560551
– fundername: ;
  grantid: CXPY201908
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
~8M
PMFND
3V.
7QP
7TK
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c540t-475ebf5b1ed17177dfd35e9fc956ad1d82c32979a634524f1799d10212332f7c3
IEDL.DBID M48
ISSN 1472-6823
IngestDate Wed Aug 27 01:29:22 EDT 2025
Thu Aug 21 18:04:19 EDT 2025
Thu Jul 10 19:34:57 EDT 2025
Fri Jul 25 07:58:22 EDT 2025
Tue Jun 17 20:56:28 EDT 2025
Tue Jun 10 20:12:51 EDT 2025
Tue Jul 01 01:37:13 EDT 2025
Thu Apr 24 23:12:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-475ebf5b1ed17177dfd35e9fc956ad1d82c32979a634524f1799d10212332f7c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2435232535?pq-origsite=%requestingapplication%
PMID 32698889
PQID 2435232535
PQPubID 44656
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_34408d2ce2ef4285b393288b3e5ba402
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7376964
proquest_miscellaneous_2426537410
proquest_journals_2435232535
gale_infotracmisc_A631902478
gale_infotracacademiconefile_A631902478
crossref_citationtrail_10_1186_s12902_020_00563_y
crossref_primary_10_1186_s12902_020_00563_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-07-22
PublicationDateYYYYMMDD 2020-07-22
PublicationDate_xml – month: 07
  year: 2020
  text: 2020-07-22
  day: 22
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle BMC endocrine disorders
PublicationYear 2020
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References H Sun (563_CR15) 2019; 488
YF Peng (563_CR23) 2016; 30
SH Lee (563_CR9) 2018; 29
P Cheriyath (563_CR4) 2010; 2
M Shiraishi (563_CR7) 2019; 11
TW Wu (563_CR22) 1994; 54
KH Wagner (563_CR5) 2015; 129
R Kawamoto (563_CR29) 2019; 13
R Vona (563_CR2) 2019; 2019
L Vitek (563_CR17) 2012; 3
JA Zhou (563_CR34) 2017; 16
E Mccracken (563_CR3) 2018; 36
AC Bulmer (563_CR18) 2013; 52
J Neuzil (563_CR21) 1994; 269
XH Zhang (563_CR11) 2016; 13
R Takei (563_CR26) 2019; 14
DL Mendrick (563_CR1) 2018; 162
G Heng (563_CR13) 2011; 19
H Dong (563_CR27) 2014; 155
AC Boon (563_CR19) 2014; 307
E Oda (563_CR30) 2013; 50
X Zhao (563_CR24) 2019; 2019
AC Boon (563_CR35) 2015; 86
JP Lin (563_CR37) 2010; 56
KG Alberti (563_CR14) 2009; 120
S Gazzin (563_CR20) 2016; 22
SS Huang (563_CR28) 2015; 128
JH Hwang (563_CR16) 2013; 28
T Maruhashi (563_CR32) 2012; 126
GL Mazzone (563_CR25) 2009; 386
XH Li (563_CR31) 2017; 2017
MF McCarty (563_CR36) 2007; 69
RK Schindhelm (563_CR8) 2007; 191
VL Sundararaghavan (563_CR33) 2018; 32
S Wang (563_CR6) 2017; 7
D Pei (563_CR10) 2015; 21
SX Guo (563_CR12) 2016; 6
References_xml – volume: 56
  start-page: 1535
  issue: 10
  year: 2010
  ident: 563_CR37
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2010.151043
– volume: 36
  start-page: 14
  issue: 1
  year: 2018
  ident: 563_CR3
  publication-title: Clin Dermatol
  doi: 10.1016/j.clindermatol.2017.09.004
– volume: 13
  start-page: 428
  issue: 4
  year: 2016
  ident: 563_CR11
  publication-title: Int J Environ Res Public Health
  doi: 10.3390/ijerph13040428
– volume: 13
  start-page: 1329
  issue: 2
  year: 2019
  ident: 563_CR29
  publication-title: Diabetes Metab Syndr
  doi: 10.1016/j.dsx.2019.02.009
– volume: 386
  start-page: 338
  issue: 2
  year: 2009
  ident: 563_CR25
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2009.06.029
– volume: 52
  start-page: 193
  issue: 2
  year: 2013
  ident: 563_CR18
  publication-title: Prog Lipid Res
  doi: 10.1016/j.plipres.2012.11.001
– volume: 86
  start-page: 259
  year: 2015
  ident: 563_CR35
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2015.05.031
– volume: 307
  start-page: 123
  issue: 2
  year: 2014
  ident: 563_CR19
  publication-title: Am J Physiol Renal Physiol
  doi: 10.1152/ajprenal.00039.2014
– volume: 7
  start-page: 44844
  year: 2017
  ident: 563_CR6
  publication-title: Sci Rep
  doi: 10.1038/srep44844
– volume: 2017
  start-page: 9621615
  year: 2017
  ident: 563_CR31
  publication-title: Biomed Res Int
– volume: 19
  start-page: 538
  issue: 06
  year: 2011
  ident: 563_CR13
  publication-title: Chin J Hypertension
– volume: 11
  start-page: 12
  year: 2019
  ident: 563_CR7
  publication-title: Diabetol Metab Syndr
  doi: 10.1186/s13098-019-0408-z
– volume: 6
  start-page: 36091
  year: 2016
  ident: 563_CR12
  publication-title: Sci Rep
  doi: 10.1038/srep36091
– volume: 21
  start-page: 158
  issue: 3
  year: 2015
  ident: 563_CR10
  publication-title: Saudi J Gastroenterol
  doi: 10.4103/1319-3767.157564
– volume: 126
  start-page: 598
  issue: 5
  year: 2012
  ident: 563_CR32
  publication-title: Circulation.
  doi: 10.1161/CIRCULATIONAHA.112.105775
– volume: 28
  start-page: 1768
  issue: 12
  year: 2013
  ident: 563_CR16
  publication-title: J Korean Med Sci
  doi: 10.3346/jkms.2013.28.12.1768
– volume: 155
  start-page: 818
  issue: 3
  year: 2014
  ident: 563_CR27
  publication-title: Endocrinology.
  doi: 10.1210/en.2013-1667
– volume: 32
  start-page: 234
  issue: 4
  year: 2018
  ident: 563_CR33
  publication-title: Transplant Rev (Orlando)
  doi: 10.1016/j.trre.2018.06.003
– volume: 269
  start-page: 16712
  issue: 24
  year: 1994
  ident: 563_CR21
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(19)89449-8
– volume: 14
  start-page: e223302
  issue: 10
  year: 2019
  ident: 563_CR26
  publication-title: PLoS One
– volume: 54
  start-page: 477
  issue: 25
  year: 1994
  ident: 563_CR22
  publication-title: Life Sci
  doi: 10.1016/0024-3205(94)90140-6
– volume: 2019
  start-page: 8267234
  year: 2019
  ident: 563_CR2
  publication-title: Oxidative Med Cell Longev
  doi: 10.1155/2019/8267234
– volume: 3
  start-page: 55
  year: 2012
  ident: 563_CR17
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2012.00055
– volume: 30
  start-page: 982
  issue: 6
  year: 2016
  ident: 563_CR23
  publication-title: J Clin Lab Anal
  doi: 10.1002/jcla.21967
– volume: 488
  start-page: 242
  year: 2019
  ident: 563_CR15
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2018.10.033
– volume: 50
  start-page: 417
  issue: 3
  year: 2013
  ident: 563_CR30
  publication-title: Acta Diabetol
  doi: 10.1007/s00592-012-0447-5
– volume: 2019
  start-page: 5256460
  year: 2019
  ident: 563_CR24
  publication-title: Mediat Inflamm
– volume: 22
  start-page: 758
  issue: 9
  year: 2016
  ident: 563_CR20
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2016.07.004
– volume: 2
  start-page: 201
  issue: 5
  year: 2010
  ident: 563_CR4
  publication-title: J Clin Med Res
– volume: 129
  start-page: 1
  issue: 1
  year: 2015
  ident: 563_CR5
  publication-title: Clin Sci (Lond)
  doi: 10.1042/CS20140566
– volume: 128
  start-page: 1135
  issue: 10
  year: 2015
  ident: 563_CR28
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2015.05.016
– volume: 29
  start-page: 52
  issue: 1
  year: 2018
  ident: 563_CR9
  publication-title: Turk J Gastroenterol
  doi: 10.5152/tjg.2018.17333
– volume: 69
  start-page: 974
  issue: 5
  year: 2007
  ident: 563_CR36
  publication-title: Med Hypotheses
  doi: 10.1016/j.mehy.2006.12.069
– volume: 162
  start-page: 36
  issue: 1
  year: 2018
  ident: 563_CR1
  publication-title: Toxicol Sci
  doi: 10.1093/toxsci/kfx233
– volume: 120
  start-page: 1640
  issue: 16
  year: 2009
  ident: 563_CR14
  publication-title: Circulation.
  doi: 10.1161/CIRCULATIONAHA.109.192644
– volume: 16
  start-page: 1779
  issue: 2
  year: 2017
  ident: 563_CR34
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2017.6825
– volume: 191
  start-page: 391
  issue: 2
  year: 2007
  ident: 563_CR8
  publication-title: Atherosclerosis.
  doi: 10.1016/j.atherosclerosis.2006.04.006
SSID ssj0017820
Score 2.2625682
Snippet Background Some studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of transaminase is...
Some studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of transaminase is a risk...
Abstract Background Some studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Age
Analysis
Bilirubin
Blood pressure
Cholesterol
Diabetes
Gender
Hypertension
Insulin resistance
Liver
Metabolic syndrome
Metabolites
Minority & ethnic groups
Population
Risk factors
Studies
Transaminase
Type 2 diabetes
Variables
Women
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDxUXxFMEWmQkJA7I6sbvHAtqVYHKiUp7s_wKXSgJ6mYP5dd3Jo_VpkjlwjV2Xp4Zzzf2-BtC3oUsa3CUkWmpPZM8lMxDEMZ0VjbbVKbo8TTy-Vd9diE_L9Vyp9QX5oQN9MDDwB0JLImceMw81wCVVRCAOKwNIqvg5UAjCT5vCqbG_QNkgZuOyFh9tMbVFs4wVELuS8FuZm6oZ-v_e06-mye543hOH5NHI2Kkx8OXPiEPcvOU7J-Pe-LPSLszwrStadcCnqaY83q9gbCX-iZR3JjGqW3nMuaowwspLsTSX7kDZbhaRToxGNC-ChH94v_4n5dreABdrpofoEvfn5OL05Nvn87YWEaBRYBjHZNG5VCrUOZUQvBmUp2EylUdITTyIA3Lo-CVqbwWUnFZI0dcworfXAhemyhekL2mbfJLQssylgufU5CLLL0yoUrR8lQCTBdiEeqClNOoujhyjGOpiyvXxxpWu0ESDiThekm4m4J82N7ze2DYuLf3RxTWtieyY_cXQGfcqDPuXzpTkPcoaoc2DJ8X_XgUAX4S2bDcsYaJCcCLsQU5mPUE24vz5klZ3Gj7a8cBgQJOVUIV5O22Ge_EfLYmtxvsw7USgOYWBTEzJZv92bylWV32_N8GnEKl5av_MRSvyUPem4VhnB-Qve56kw8BZnXhTW9Rt4kpJNA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIhLxVOEFmQkJA7I6voVJydUEFUFKicq7c3yK-1CScpu9lB-PTNZZ9mA1GvsPJwZz8xnj78h5I1PqgFHGVipSseU8Jw5AGGsTLpKVeQxODyNfPa1PD1Xn-d6nhfcVjmtcrSJg6GOXcA18iMBfh28v5b6_fUvhlWjcHc1l9C4S-4hdRmCLzPfAi6OXHDjQZmqPFrhmotgCJiQAVOym4kzGjj7_7fM_2ZL7rifk4dkP8eN9Hgj6EfkTmofk_tneWf8Cel2_jPtGtp3EFVTzHxdrgH8UtdGitvTaOB2LmOmOryQ4nIs_Zl6UImrRaAjjwEdahHRL-63-3G5ggfQ-aL9Dhp18ZScn3z69vGU5WIKLEBQ1jNldPKN9jxFDhDOxCZKneomAEByIJNKBClqU7tSKi1Ug0xxEet-CylFY4J8Rvbark3PCeU88JlL0atZUk4bX8dQicghWJdy5puC8PGv2pCZxrHgxZUdEEdV2o0kLEjCDpKwNwV5t73nesOzcWvvDyisbU_kyB4udMsLm6eclVhMO4qQRGoAZGkvIVatKi-T9g5gc0HeoqgtzmT4vODygQQYJHJi2eMSzBOEMKYqyOGkJ8zAMG0elcVmC7Cyf_W1IK-3zXgnZrW1qVtjH1FqCTHdrCBmomSTkU1b2sXlwAJuwDXUpXpx-8sPyAMxKLxhQhySvX65Ti8hjOr9q2Gu_AHgnxz2
  priority: 102
  providerName: ProQuest
Title Association of total bilirubin and indirect bilirubin content with metabolic syndrome among Kazakhs in Xinjiang
URI https://www.proquest.com/docview/2435232535
https://www.proquest.com/docview/2426537410
https://pubmed.ncbi.nlm.nih.gov/PMC7376964
https://doaj.org/article/34408d2ce2ef4285b393288b3e5ba402
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zi9RAEG72APFFPDG6Di0IPkjrpI905kFkR3ZZlFlkcWDwpekru6NjonOA46-3KpOME13Elzx0d45OVXV91cdXhDxzURbgKD3LZGaZ5C5lFoIwlkWVxzykwVs8jTw6z87G8t1ETfZIm-6o-YGLa0M7zCc1ns9e_vi-fgMG_7o2-Dx7tcC5FM4wEEJmS8HW--QQPJPGVA4j-XtVAbnh6tNGmrMs56I9RHPtMzqOqubz_3vU_nMn5Y5rOr1NbjWYkh5vlOAO2YvlXXJj1Kya3yPVjgxoVdBlBZ2luCt2voLAmNoyUFy6xsFvpxh3scMLKU7V0q9xCeoym3rachzQOk8RfW9_2i9XC3gAnUzLz6Btl_fJ-PTk49sz1iRaYB4A25JJraIrlEtjSCG806EIQsVB4SF4siCvnHvBB3pgMyEVlwWyyAXMCc6F4IX24gE5KKsyPiQ0TX3atzE42Y_SKu0Gwec8pADkhei7IiFp-1eNb1jIMRnGzNTRSJ6ZjSQMSMLUkjDrhLzY3vNtw8Hxz9ZDFNa2JfJn1wXV_NI05mgEJtoO3EceCwjAlBOAY_PciaichZA6Ic9R1Ab1Dj7P2-awAnQS-bLMcQZDF8AbnSfkqNMSrNN3q1tlMa1yGw4YFZCsEiohT7fVeCfueCtjtcI2PFMC8F4_IbqjZJ2edWvK6VXNEK7BbQwy-ei_e_GY3OS17mvG-RE5WM5X8QmgraXrkX090T1yODw5_3DRq-cserVZwfVi-OkXcfUq6g
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJwEviKsWGGAkEA_IWuNLkj4gtMGmjq4VQpu0N-NbtsJIRi9C5UfxGzknTUoD0t72Gjt2nHP97ONzCHlpg8zBUDqWyMQwyW3MDIAwlgSVhczH3hm8jTwcJf0T-fFUnW6Q381dGAyrbHRipah96XCPfIeDXQfrr4R6d_mDYdUoPF1tSmgs2WIQFj8Bsk3fHn4A-r7i_GD_-H2f1VUFmAPvZMZkqoLNlY2DjwHLpD73QoVe7gApGPi4jDvBe2nPJEIqLnNMmeaxADYXguepEzDuDbIpBbgKHbK5tz_69Hl1boHZ55qrOVmyM8VdHs4QomHOTcEWLfNXVQn43xb8G5-5ZvAO7pI7tadKd5esdY9shOI-uTmsz-IfkHKNsrTM6awEP55irO1kDnCbmsJTPBBHlbr2GGPjYUKKG8D0e5gBE16MHW0yJ9Cq-hEdmF_m2_kUBqCn4-Ir8PDZQ3JyLT_6EekUZRG2CI1jF3dN8FZ2gzQqtT3vMu5jgAdCdG0ekbj5q9rVuc2xxMaFrjBOluglJTRQQleU0IuIvFm9c7nM7HFl7z0k1qonZuWuHpSTM10LuRZYvttzF3jIAdYpK8A7zjIrgrIGgHpEXiOpNeoO-Dxn6isQsEjMwqV3E1CI4DSlWUS2Wz1B5l27uWEWXeucqf4rIRF5sWrGNzGOrgjlHPvwRAnwIrsRSVtM1lpZu6UYn1d5x1MwRr1EPr568ufkVv94eKSPDkeDJ-Q2r5g_ZZxvk85sMg9PwYmb2We15FDy5bqF9Q92sFn3
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+of+total+bilirubin+and+indirect+bilirubin+content+with+metabolic+syndrome+among+Kazakhs+in+Xinjiang&rft.jtitle=BMC+endocrine+disorders&rft.au=Hao%2C+Hao&rft.au=Guo%2C+Heng&rft.au=Ma%2C+Ru-lin&rft.au=Yan%2C+Yi-zhong&rft.date=2020-07-22&rft.pub=BioMed+Central+Ltd&rft.issn=1472-6823&rft.eissn=1472-6823&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs12902-020-00563-y&rft.externalDocID=A631902478
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1472-6823&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1472-6823&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1472-6823&client=summon